Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020
Two abstracts will be presented during the poster session on
Abstract Title: Gene therapy PR006 increased progranulin levels and improved lysosomal related phenotypes in model systems (poster #52)
Abstract Title: Gene therapy PR001 increased GCase activity and improved neuronopathic Gaucher disease phenotypes in mouse models (poster #159)
One abstract will be presented during the
Abstract Title: Gene therapy PR006 increased progranulin levels and improved lysosomal related phenotypes in model systems
Presenter: Asa Abeliovich, M.D., Ph.D.
In addition to its presentations at WORLDSymposium, on
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company is developing PR001 for patients with Parkinson’s disease with a GBA1 mutation (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia with GRN mutation (FTD-GRN); and PR004 for patients with certain synucleinopathies.
Prevail was founded by Dr.
Forward-Looking Statements Related to Prevail
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning Prevail’s ability to develop meaningful therapeutic advances for patients with neurodegenerative diseases. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Prevail’s novel approach to gene therapy makes it difficult to predict the time, cost and potential success of product candidate development or regulatory approval; Prevail’s gene therapy programs may not meet safety and efficacy levels needed to support ongoing clinical development or regulatory approval; the regulatory landscape for gene therapy is rigorous, complex, uncertain and subject to change; and the fact that gene therapies are novel, complex and difficult to manufacture. These and other risks are described more fully in Prevail’s filings with the
Source: Prevail Therapeutics